How Pfizer CentreOne unlocks the power of Pfizer experts for CDMO partners

Pfizer CentreOne is an “altogether different kind of CDMO”. Unlike a pure play contract development and manufacturing partner, they don’t own their own plants and pharmaceutical development centres. Instead their customers can leverage the wealth of expertise and state-of-the-art facilities Pfizer possesses.

Ahead of CDMO Live 2024 we sat down with Tom Wilson, VP of Global Contract Manufacturing at Pfizer CentreOne, to discuss how their integrated business model sets them apart from other contract manufacturing partners.

Pfizer CentreOne offers a comprehensive range of services including small molecule API, solid oral dose, sterile injectables, biologics, and cell & gene therapies.

“Pfizer spends over a billion dollars every year to maintain our global network of 38 plants.” says Tom.

“When we bring a client partner on board, they get access to the same manufacturing work centres, scientists, and analysts that Pfizer uses for its products. We have robust ways of controlling intellectual property, ensuring we’re protecting our clients and our own IP.”

“Pfizer’s main mission statement is ‘time is life’. We bring that patient centricity to our CDMO practice. Clients are usually surprised that we’re not talking immediately about our technology, but instead about their patient’s journey, then how can we help make a difference.”

Read the full article